Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From iCAD Inc.
The global market for breast cancer imaging and biopsy technologies is expected to reach $5.8bn by 2022, a CAGR of 5.9%, driven by innovation technologies and machine-learning tools that serve as "second readers" to help radiologists triage images and find cancers. Many radiologists believe that mammography will remain the most widely used screening tool, but that digital breast tomosynthesis will ultimately become the gold standard. Here's a close look at the overall breast imaging and biopsy market, highlighting different modalities and key players, and offering the real-world use perspective from three radiologists at Kaiser Permanente, San Diego.
The unexpected firing of Arcturus CEO Joseph Payne kicked off a bitter public battle for control of the RNA therapeutics firm after a reverse merger with Alcobra in November. The dispute now settled, the new board has reinstated Payne at Arcturus' helm.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in August 2017.
The German-headquartered firm is making a play to enter the US vascular intervention market, with two stents approved by FDA under original PMAs in the first quarter of 2017. Cardiovascular devices, in general, have gained the most novel-device approvals so far this year, followed by IVDs. Check out more from a Q1 look at US FDA approvals and clearances monitored by Medtech Insight's Approvals Tracker.
- Diagnostic Equipment & Supplies
Diagnostic Imaging Equipment & Supplies
- Digital Imaging
- MRI, NMR
- Artificial Intelligence
- Other Names / Subsidiaries
- HOWTEK, Inc.
- Xoft, Inc.
- Qualia Computing Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.